- BeyondSpring Inc BYSI has submitted marketing applications in the U.S. and China seeking approval for plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
- Neutropenia is a condition wherein a person has a low level of neutrophils, a white blood cell that helps the body fight infection.
- The submission is based on data from PROTECTIVE-2 Phase 3 study, which showed that plinabulin combined with pegfilgrastim demonstrated superior CIN prevention benefit compared to pegfilgrastim alone.
- The study met the primary endpoint, with a statistically significant improvement in the rate of prevention of grade 4 neutropenia (improved from 13.6% to 31.5%).
- Price Action: BYSI shares are up 4.1% higher at $11.07 in the premarket trading on the last check Thursday.
Loading...
Loading...
BYSIBeyondSpring Inc
$2.456.99%
Edge Rankings
Momentum
75.30
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.